Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically documented solid tumor that is
refractory to conventional therapy or for which no conventional treatment exists No
primary or secondary brain tumor No CNS disease or treatment-related CNS dysfunction No
bone metastases involving 4 or more sites

PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Life expectancy: At
least 8 weeks Hematopoietic: Absolute neutrophil count greater than 1,500 Platelet count
greater than 100,000 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no
greater than 1.5 mg/dL Other: No active infection No history of egg protein allergy No
prior gastric or small intestine resection or clinical evidence of malabsorption No
history of medical, neurologic, or psychiatric disorder No concomitant medical problem
unrelated to the malignancy that precludes study compliance or increases treatment risk No
pregnant women Adequate contraception required of fertile patients

PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No
more than 4 courses of combination chemotherapy that included an alkylating agent,
cisplatin, or carboplatin (applies once grade 1 or worse myelosuppression is reported on
this study) No prior mitomycin or nitrosoureas At least 28 days since chemotherapy No
concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior
radiotherapy to wide ports involving pelvis or 20% of bone marrow At least 28 days since
large-field radiotherapy No concurrent radiotherapy Surgery: At least 14 days since major
surgery Other: No bone marrow transplantation